Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
©2013 UpToDate ® Print Email Fractures in the major randomized aromatase inhibitor trials Trial N/n F/U, mo Treatment Clinical fracture rate, percent AI vs TAM ATAC 9366/609 100 ANA vs TAM 11.0 vs 7.7 [p<0.001] BIG 1-98 4922/352 51 LET vs TAM 8.6 vs 5.8 [p<0.01] AI after 2-3 years of TAM IES 4724/277 58 EXE vs TAM 7.0 vs 5.0 [p = 0.003] ABCSG8/ARNO 3224/50 28 ANA vs TAM 2.0 vs 1.0 [p = 0.015] AI after 5 years of TAM MA-17 5187/256 30 LET vs Placebo 5.3 vs 4.6 [p = 0.25] ANA: anastrozole; TAM: tamoxifen; EXE: exemestane; LET: letrozole; F/U: follow-up; BMD: bone mineral density; N: number of patients treated; n: total number of fractures. Reproduced with permission from: Pant, S, Shapiro, CL. Aromatase inhibitor-associated bone loss. Drugs 2008; 68:2591. Copyright ©2008 Adis Data Information BV.